Conexeu Sciences Launches Human Collagen Initiative for Regenerative Aesthetics as GLP-1 Drives Demand for Tissue Restoration
Key Highlights
- ➤Human collagen pilot batch met predefined identity and structure specifications
- ➤P.R.O.O.F.™ study met objectives across facial and 200cc-equivalent models
- ➤Conexeu targets FDA 510(k) submission for CXU™ in Q1 2027
- ➤CXU™ designed as a temporary scaffold, unlike conventional volumizing fillers
Expert Statements
Miles Harrison, President and Chief Executive Officer of Conexeu Sciences
“GLP-1 has created a new patient profile: people whose bodies have changed faster than today’s aesthetic injectables were built to address, and restoring that tissue takes more than volume”
Miles Harrison, President and Chief Executive Officer of Conexeu Sciences
“Human collagen is an important ingredient, but on its own it does not recreate the complexity of native extracellular matrix. We believe the patented CXU™ formula provides a broader ECM framework than collagen alone and may offer a differentiated scaffold-based approach to aesthetics, based on more than a decade of university research and more than two years of development at Conexeu. That is why we believe we are well positioned to bring human collagen into aesthetics.”
Dr. Claudia Chavez-Munoz, Chief Scientific Officer of Conexeu Sciences
“CXU™ is designed to go in as a liquid, set into a gel at body temperature, and become a temporary scaffold that the body’s own cells move into and remodel. In our 12-month P.R.O.O.F.™ study, the formula met its objectives with human collagen from multiple sources. Our first pilot batch is an early step toward making human collagen ourselves, to our own specifications.”
Conexeu has launched a human collagen initiative at its Vancouver research and development facility, for its aesthetics program, focused on potential tissue-restoration applications associated with aging and significant weight loss, including GLP-1-associated weight loss. * The patented CXU™ formula has already been evaluated with human collagen from various sources in the 12-month P.R.O.O.F.™ preclinical study, which met its objectives in facial and large-volume models. * Conexeu’s first pilot batch of its own human collagen met predefined Company specifications, a first step toward controlling quality from the ingredient to the finished device. * CXU™ is being developed as a temporary collagen-based scaffold intended to provide structural support while host tissue interacts with and remodels the matrix, a different design concept from conventional dermal fillers used primarily for volumization or biostimulation. * Conexeu continues to target its planned FDA 510(k) submission for device candidate CXU™ in the first calendar quarter of 2027, subject to successful completion of required testing, manufacturing activities and regulatory documentation. RENO, Nev., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Conexeu Sciences Inc. (Nasdaq: CNXU) (“Conexeu” or the “Company”), a preclinical-stage medical device and regenerative medicine company advancing CXU™, an investigational tissue-restoration platform, today announced a human collagen program for regenerative aesthetics, starting with the production of its first pilot batch of human type I collagen.
Get started
Create a free account to read the full story.